文献速递头颈部肿瘤放疗

头颈部皮肤癌的立体定向体部放疗结局

Stereotactic body radiotherapy for head and neck skin cancer.
PubMed 文献 · Radiother Oncol · 2021-10-11

中位随访8个月,1年和2年局部控制率分别为78%和67%;31%出现≥3级急性毒性,8%出现≥3级晚期毒性,无治疗相关死亡。SBRT对此类高风险患者可获得持久疾病控制且毒性可接受。

要点

  • 不适合标准根治的高龄头颈部皮肤癌患者可考虑SBRT。
  • 1年和2年局部控制率分别为78%和67%。
  • ≥3级急性毒性31%,≥3级晚期毒性8%,无治疗相关死亡。

核心结论

  • SBRT为此类无法接受标准根治的高风险头颈部皮肤癌患者提供持久疾病控制且毒性可接受。

研究设计与样本

  • 单中心回顾性综述2012至2019年头颈部皮肤癌SBRT患者,采用Kaplan-Meier法估计结局并行单因素和多因素分析。

主要发现

  • 多数患者为晚期(总体III-IV期90例,85%),中位GTV为31 cm3(范围17-56 cm3)。
  • 治疗部位为原发51个、淋巴结47个、原发加淋巴结8个。
  • 1年和2年局部控制率分别为78%(69-88)和67%(53-82)。
  • SBRT野外1年局部区域控制率、总生存率、无进展生存率和晚期毒性率分别为72%(62-84)、53%(43-65)、52%(40-62)和7%(2-17)。

关键数值与推荐

  • SBRT剂量32-50 Gy,每周两次,分4-6次照射至大体肿瘤体积(GTV)。
  • 急性和晚期3-4级毒性按CTCAE v5.0报告。

临床怎么用

  • 对因医学原因不适合标准根治的高龄晚期头颈部皮肤癌患者,SBRT可作为可选治疗策略。
  • 治疗前应评估GTV体积和分期,治疗中及治疗后关注皮炎等急性毒性及纤维化等晚期毒性。

局限性

  • 单中心回顾性设计,中位随访仅8个月,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To report outcomes of Stereotactic Body Radiotherapy (SBRT) for head and neck skin cancer (HNSC) patients treated at a high-volume center. MATERIALS: A retrospective review of HNSC SBRT patients from 2012 to 2019 was conducted. Kaplan-Meier method was used to estimate local control (LC), locoregional control (LRC) outside of SBRT field, overall survival (OS), progression-free survival (PFS) and late toxicity (LT). Univariate and multivariate analyses were performed. Grade 3-4 acute and late toxicities were reported by the Common Terminology Criteria for Adverse Events v5.0. RESULTS: One hundred and six medically unfit HNSC patients (112 lesions) were included. Median follow-up was 8 months. Median patient age at diagnosis was 86 years (range: 56-102 years). The majority of patients had advanced disease (overall stage III-IV [n = 90, 85%]) with median gross tumor volumes (GTV) of 31 cm3 (range: 17-56 cm3). Treated sites were: primary (n = 51), nodal (n = 47) or primary plus nodal (n = 8). SBRT doses ranged from 32-50 Gy delivered twice weekly in 4-6 fractions to the gross tumor volume (GTV). One and 2-year LC rates were 78% (69-88) and 67% (53-82), respectively. One-year LRC outside of SBRT field, OS, PFS and LT rates were 72% (62-84), 53% (43-65), 52% (40-62), and 7% (2-17), respectively. Thirty-three patients (31%) developed acute grade ≥ 3 treatment-related toxicity, most commonly dermatitis (n = 31). Nine patients (8%) experienced late grade ≥ 3 toxicity, including 7 grade 3 fibrosis, 1 grade 3 bone radionecrosis and 1 grade 4 skin ulceration. No treatment-related deaths (grade 5) were observed. CONCLUSION: SBRT provides durable disease control with acceptable toxicity for medically unfit high-risk HNSC patients unable to undergo standard of care curative treatment approaches.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Voruganti IS, Poon I, Husain ZA, et al. Stereotactic body radiotherapy for head and neck skin cancer. Radiother Oncol. 2021. PMID: 34648871. doi:10.1016/j.radonc.2021.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。